NEW YORK, Nov. 18, 2015 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Osiris Therapeutics, Inc. ("Osiris" or the "Company") (NasdaqGM: OSIR -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
The investigation concerns whether Osiris and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934
On November 16, 2015, Osiris filed its 10-Q Quarterly Report, disclosing multiple restatements in prior financial results, including three restatements made related to distributor relationships. As a result of these adjustments, Osiris missed revenue targets in three of the last four quarters.
Following this news, Osiris stock fell $3.02 or 21.53% to close at $10.97 on November 17, 2015.
If you are aware of any facts relating to this investigation, or purchased shares of Osiris, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
info@bgandg.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-osiris-therapeutics-inc-300180657.html
SOURCE Bronstein, Gewirtz & Grossman, LLC